Association between glycosylated hemoglobin A1c/high density lipoprotein-cholesterol ratio and severity of coronary artery disease

doi:10.3969/j.issn.1006-7795.2025.06.015

Abstract

Abstract: Objective To investigate the association between the ratio of glycosylated hemoglobin A1c to high density lipoprotein-cholesterol (HbA1c/HDL-C) and the severity of coronary artery lesion, specifically focusing on triple-vessel involvement. Methods In this retrospective study, 313 patients diagnosed with coronary heart disease (CHD) through coronary angiography at the Cardiovascular Center of Beijing Tongren Hospital, Capital Medical University between June 2023 and September 2024 were divided into three groups: single-vessel disease (n=110), double-vessel disease (n=95), and triple-vessel disease (n=108). Univariate and multivariate Logistic regression were used to evaluate the association between HbA1c/HDL-C and triple-vessel disease, with subsequent subgroup analysis performed. The receiver operating characteristic (ROC) curve analysis was applied to evaluate the diagnostic performance of HbA1c/HDL-C for triple-vessel coronary artery disease. Spearman correlation analysis was utilized to examine the relationship between HbA1c/HDL-C and Gensini score. Results The triple-vessel disease group had significantly higher HbA1c/HDL-C level than the single-vessel and double-vessel groups (P<0.001). Multivariate Logistic regression demonstrated that HbA1c/HDL-C remained independently associated with triple-vessel coronary artery lesion, regardless of its categorization as a continuous or categorical variable, with no significant interaction observed across subgroups. The results of ROC curve analysis showed that the area under the ROC curve of HbA1c/HDL-C for identifying triple-vessel coronary artery disease was 0.685 (95%CI: 0.625－0.746), the specificity was 58.5%, the sensitivity was 70.4%, and the optimal cut-off value was 5.63. Further analysis demonstrated that incorporating HbA1c/HDL-C into conventional clinical models significantly enhanced discriminative performance (net reclassification improvement, NRI=0.258, P=0.029; integrated discrimination improvement, IDI=0.021, P=0.013). Spearman correlation analysis revealed a statistically significant positive correlation between HbA1c/HDL-C and Gensini score (r=0.257, P＜0.001). Conclusion HbA1c/HDL-C is significantly associated with the risk of triple-vessel coronary artery disease, serving as an independent factor of coronary lesion severity. It has relatively good discriminatory efficacy for triple-vessel coronary artery disease.

Key words: glycosylated hemoglobin A1c/high density lipoprotein-cholesterol ratio, coronary heart disease, , coronary artery disease, triple-vessel coronary artery disease, Gensini score, coronary angiography

CLC Number:

R541

Xin Yu, Jiang Xue, Guo Caixia. Association between glycosylated hemoglobin A1c/high density lipoprotein-cholesterol ratio and severity of coronary artery disease[J]. Journal of Capital Medical University, 2025, 46(6): 1073-1081.

References

［1］刘明波, 何新叶, 杨晓红, 等. 《中国心血管健康与疾病报告2023》要点解读［J］. 中国心血管杂志, 2024, 29(4): 305-324.
［2］Reynolds H R, Shaw L J, Min J K, et al. Outcomes in the ISCHEMIA trial based on coronary artery disease and ischemia severity［J］. Circulation, 2021, 144(13): 1024-1038.
［3］Min J K, Dunning A, Lin F Y, et al. Age-and sex-related differences in all-cause mortality risk based on coronary computed tomography angiography findings results from the international multicenter CONFIRM (coronary CT angiography evaluation for clinical outcomes: an international multicenter registry) of 23 854 patients without known coronary artery disease［J］. J Am Coll Cardiol, 2011, 58(8): 849-860.
［4］Lopes N H, Paulitsch Fda S, Gois A F, et al. Impact of number of vessels disease on outcome of patients with stable coronary artery disease: 5-year follow-up of the medical, angioplasty, and bypass surgery study (MASS)［J］. Eur J Cardiothorac Surg, 2008, 33(3): 349-354.
［5］Liu Z P, Li J P, Zhang Y, et al. Trends in percutaneous coronary intervention in China: analysis of China PCI registry data from 2010 to 2018［J］. Cardiology Plus, 2022, 7: 118-124.
［6］Makris K, Spanou L. Is there a relationship between mean blood glucose and glycated hemoglobin?［J］. J Diabetes Sci Technol, 2011, 5(6): 1572-1583.
［7］Hong L F, Li X L, Guo Y L, et al. Glycosylated hemoglobin A1c as a marker predicting the severity of coronary artery disease and early outcome in patients with stable angina［J］. Lipids Health Dis, 2014, 13: 89.
［8］Alber H F, Wanitschek M M, De Waha S, et al. High-density lipoprotein cholesterol, C-reactive protein, and prevalence and severity of coronary artery disease in 5641 consecutive patients undergoing coronary angiography［J］. Eur J Clin Invest, 2008, 38(6): 372-380.
［9］Parhofer K G. Interaction between glucose and lipid metabolism: more than diabetic dyslipidemia［J］. Diabetes Metab J, 2015, 39(5): 353-362.
［10］Hu X M, Li W, Wang C Y, et al. Association between the plasma-glycosylated hemoglobin A1c/high-density lipoprotein cholesterol ratio and carotid atherosclerosis: a retrospective study［J］. J Diabetes Res, 2021, 2021: 9238566.
［11］Gui M H, Qin G Y, Ning G, et al. The comparison of coronary angiographic profiles between diabetic and nondiabetic patients with coronary artery disease in a Chinese population［J］. Diabetes Res Clin Pract, 2009, 85(2): 213-219.
［12］Garg N, Moorthy N, Kapoor A, et al. Hemoglobin A1c in nondiabetic patients: an independent predictor of coronary artery disease and its severity［J］. Mayo Clin Proc, 2014, 89(7): 908-916.
［13］Jiao X J, Zhang Q, Peng P, et al. HbA1c is a predictive factor of severe coronary stenosis and major adverse cardiovascular events in patients with both type 2 diabetes and coronary heart disease［J］. Diabetol Metab Syndr, 2023, 15(1): 50.
［14］Won K B, Lee B K, Lin F Y, et al. Glycemic control is independently associated with rapid progression of coronary atherosclerosis in the absence of a baseline coronary plaque burden: a retrospective case-control study from the PARADIGM registry［J］. Cardiovasc Diabetol, 2022, 21(1): 239.
［15］Dykun I, Bayturan O, Carlo J, et al. HbA1c, coronary atheroma progression and cardiovascular outcomes［J］. Am J Prev Cardiol, 2022, 9: 100317.
［16］Cheng Y, Zou J, Chu R, et al. Cumulative HbA1c exposure as a CVD risk in patients with type 2 diabetes: a post hoc analysis of ACCORD trial［J］. Diabetes Res Clin Pract, 2023, 206: 111009.
［17］Huang D, Huang Y Q, Zhang Q Y, et al. Association between long-term visit-to-visit hemoglobin A1c and cardiovascular risk in type 2 diabetes: the ACCORD trial［J］. Front Cardiovasc Med, 2021, 8: 777233.
［18］Jia G, Bai H, Mather B, et al. Diabetic vasculopathy: molecular mechanisms and clinical insights［J］. Int J Mol Sci, 2024, 25(2): 804.
［19］Biddinger S B, Hernandez-Ono A, Rask-Madsen C, et al. Hepatic insulin resistance is sufficient to produce dyslipidemia and susceptibility to atherosclerosis［J］. Cell Metab, 2008, 7(2): 125-134.
［20］Poznyak A, Grechko A V, Poggio P, et al. The diabetes mellitus-atherosclerosis connection: the role of lipid and glucose metabolism and chronic inflammation［J］. Int J Mol Sci, 2020, 21(5): 1835.
［21］Hoofnagle A N, Vaisar T, Mitra P, et al. HDL lipids and insulin resistance［J］. Curr Diab Rep, 2010, 10(1): 78-86.
［22］Li N S, Fu J Y, Koonen D P, et al. Are hypertriglyceridemia and low HDL causal factors in the development of insulin resistance?［J］. Atherosclerosis, 2014, 233(1): 130-138.
［23］Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease［J］. JAMA, 2009, 302(18): 1993-2000.
［24］Wang Y, Yan T, Yang Y X, et al. Association between changes in high-density lipoprotein cholesterol and risk of cardiovascular disease［J］. J Clin Lipidol, 2024, 18(6): e1025-e1034.
［25］Ballantyne C M, Herd J A, Ferlic L L, et al. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy［J］. Circulation, 1999, 99(6): 736-743.
［26］Liu H H, Guo Y L, Wu N Q, et al. High-density lipoprotein cholesterol levels are associated with coronary severity but not with outcomes in new-onset patients with stable coronary artery disease［J］. Atherosclerosis, 2017, 263: 104-111.
［27］Yang H S, Jeong H J, Kim H, et al. Sex-specific U-shaped relationships between high-density lipoprotein cholesterol levels and 10-year major adverse cardiovascular events: a nationwide cohort study of 5.7 million South Koreans［J］. Ann Lab Med, 2022, 42(4): 415-427.
［28］Lui D T W, Li L L, Liu X D, et al. The association of HDL-cholesterol levels with incident major adverse cardiovascular events and mortality in 0.6 million individuals with type 2 diabetes: a population-based retrospective cohort study［J］. BMC Med, 2024, 22(1): 586.
［29］Endo Y, Fujita M, Ikewaki K. HDL Functions-current status and future perspectives［J］. Biomolecules, 2023, 13(1): 105.
［30］Mete M, Wilson C, Lee E T, et al. Relationship of glycemia control to lipid and blood pressure lowering and atherosclerosis: the SANDS experience［J］. J Diabetes Complications, 2011, 25(6): 362-367.
［31］Zhang X D, Van Der Vorst E P C. High-density lipoprotein modifications: causes and functional consequences in type 2 diabetes mellitus［J］. Cells, 2024, 13(13): 1113.
［32］Abbasi A, Corpeleijn E, Gansevoort R T, et al. Role of HDL cholesterol and estimates of HDL particle composition in future development of type 2 diabetes in the general population: the PREVEND study［J］. J Clin Endocrinol Metab, 2013, 98(8): E1352-E1359.
［33］Lee S H, Kim H S, Park Y M, et al. HDL-cholesterol, its variability, and the risk of diabetes: a nationwide population-based study［J］. J Clin Endocrinol Metab, 2019, 104(11): 5633-5641.
［34］He S M, Lu S, Yu C H, et al. The newly proposed plasma-glycosylated hemoglobin A1c/high-density lipoprotein cholesterol ratio serves as a simple and practical indicator for screening metabolic associated fatty liver disease: an observational study based on a physical examination population［J］. BMC Gastroenterol, 2024, 24(1): 274.
［35］Huang C J, You H T, Zhang Y Y, et al. Association between the hemoglobin A1c/high-density lipoprotein cholesterol ratio and stroke incidence: a prospective nationwide cohort study in China［J］. Lipids Health Dis, 2025, 24(1): 25.
［36］Sun F, Yu X J, Huang X H, et al. The association between glycated hemoglobin to high density lipoprotein cholesterol ratio and risk of cardiovascular diseases caused death among adult cancer survivors: evidence from NHANES 1999-2018［J］. Lipids Health Dis, 2025, 24(1): 149.

[1]	Shen Xueqian, Xin Yu , Wu Zhenyan, Wu Haosheng, Yu Panpan, Jiang Xue , Guo Caixia. Predictive value of multiple composite inflammatory indices for the severity of coronary artery lesions [J]. Journal of Capital Medical University, 2025, 46(6): 1065-1072.
[2]	Shen Xueqian, Jiang Xue, Guo Caixia. Biomarker potential and regulatory mechanisms of sRAGE in cardiovascular diseases [J]. Journal of Capital Medical University, 2025, 46(6): 1082-1092.
[3]	Tong Yuanyuan, Xie Sining, Chen Liang, Li Xiangjiahui, Han Ruquan, Xiong Wei. Comparison of laryngeal mask airway and endotracheal intubation general anesthesia for pulse generator implantation surgery in Parkinson's disease patients [J]. Journal of Capital Medical University, 2025, 46(5): 820-825.
[4]	Guo Yan, Xia Enlan, Xiao Yu, Huang Xiaowu. Multivariate analysis of pregnancy outcomes after transcervical resection of polyp in infertility patients [J]. Journal of Capital Medical University, 2025, 46(4): 724-728.
[5]	Jiang Haiping, Yin Shuo, Li Shenglan, Li Wenbin. The progress in the role and application of neutrophils in glioma [J]. Journal of Capital Medical University, 2025, 46(3): 448-454.
[6]	Huo Bixiu, Jia Hongxiao, , Ning Yanzhe, Zheng Sisi. Abnormal top-down and bottom-up attention patterns in patients suffering from coronary heart disease with heart qi deficiency syndrome [J]. Journal of Capital Medical University, 2025, 46(3): 455-462.
[7]	Huang Min. Resting energy expenditure of overweight and obese people and its correlation with body compositions [J]. Journal of Capital Medical University, 2025, 46(3): 581-585.
[8]	Zi Xiaohui, Xia Xue, Li jing, Zhang Xiaoli, Zhou Quan, Wang Anxin, Wang Yilong. Advances in the application of antiplatelet therapy in intravenous thrombolysis for acute ischemic stroke patients [J]. Journal of Capital Medical University, 2025, 46(2): 234-242.
[9]	Wang Yinping, Meng Cancan, Wu Wenjuan, Yang Zhitang. The expressions of CD62P, CD40L, and Rev-erbα after ischemic stroke on different onset times [J]. Journal of Capital Medical University, 2025, 46(1): 34-40.
[10]	Wei Xingmei, Xue Shujin, Gao Zhencheng, Li Yongxin. The application of artificial intelligence in cochlear implantation [J]. Journal of Capital Medical University, 2024, 45(6): 931-937.
[11]	Wu Zhaozhen, Zheng Hua, Sheng Shuyan, Zhang Quan, Zhang Hui, Li Jie, Lyu Jialin, Qian Zhe, Wang Shouzheng, Li Xi , Hu Ying. Observation on the preliminary efficacy of neoadjuvant immunotherapy combined with chemotherapy in non-small cell lung cancer [J]. Journal of Capital Medical University, 2024, 45(4): 642-648.
[12]	Zhang Daqian, Zhang Xiaoxin, Ye Zichen, Xie Zhilan, Yang Jichun, Jiang Yu. Diagnostic value of artificial intelligence assisted diagnostic system for acute leukemia: a Meta-analysis [J]. Journal of Capital Medical University, 2024, 45(4): 693-700.
[13]	Hou Dongyan, Feng Dan, Li Na. Efficacy of dapagliflozin in treatment of coronary heart disease and heart failure with preserved ejection fraction patients [J]. Journal of Capital Medical University, 2024, 45(4): 715-720.
[14]	Huang Xiaohui, Wang Xinwei, Wu Jie. Predictive value of neutrophil to lymphocyte ratio and platelet count combined with D-dimer in the prognosis of children with severe pneumonia complicated with sepsis [J]. Journal of Capital Medical University, 2024, 45(4): 721-726.
[15]	Liu Chang, Xin Zhong, Yang Jinkui. Relationship between diet quality scores and all-cause mortality in diabetic patients of different genders [J]. Journal of Capital Medical University, 2024, 45(3): 406-412.